Active substance
Results for the substance vosoritid
3 results
About this active substance
Vosoritide is a medication used for the treatment of achondroplasia, a rare genetic condition that affects bone growth and leads to disproportionate short stature. It is an analog of C-type natriuretic peptide (CNP) that works by inhibiting excessive signaling of the FGFR3 receptor, which is responsible for slowing bone growth in achondroplasia.
Vosoritide is administered via daily subcutaneous injection, and the treatment is indicated for children over two years of age with open growth plates.
Common side effects include injection site reactions, vomiting, fever, and joint pain. In rare cases, severe adverse reactions such as allergic reactions or kidney function impairment may occur.
Patients receiving vosoritide should undergo regular monitoring for bone growth and signs of adverse reactions. The medication represents a promising option for managing achondroplasia, helping to improve bone growth and the quality of life for patients affected by this condition.
Vosoritide is administered via daily subcutaneous injection, and the treatment is indicated for children over two years of age with open growth plates.
Common side effects include injection site reactions, vomiting, fever, and joint pain. In rare cases, severe adverse reactions such as allergic reactions or kidney function impairment may occur.
Patients receiving vosoritide should undergo regular monitoring for bone growth and signs of adverse reactions. The medication represents a promising option for managing achondroplasia, helping to improve bone growth and the quality of life for patients affected by this condition.
-
-
VOXZOGO 0.56mg powder and solvent for solution for injection BIOMARIN ORIGINAL MEDICINE
-
VOXZOGO 0.4mg powder and solvent for solution for injection BIOMARIN ORIGINAL MEDICINE